The bottom line: Pfizer Inc. is pressing Congress on a cluster of corporate and international tax provisions — the same provisions Senate Democrats spent early 2025 attacking as vehicles for offshore tax avoidance.

Why It Matters

Pfizer Inc. (https://app.legis1.com/lda-filings/detail?id=2076734#summary) faces a dual-front challenge in Washington: Democratic lawmakers have publicly accused the company of using the existing international tax framework to shift profits offshore, while the Republican-led reconciliation process simultaneously offered an opportunity to lock in favorable treatment of the same provisions under scrutiny. The core tension is whether Congress modifies the GILTI, FDII, and R&D expensing rules in ways that increase Pfizer's effective tax rate — or preserves the current structure. A legislative outcome that permanently extends favorable rates under IRC §§ 951A, 250, 163(j), and 174 would directly benefit Pfizer's global tax planning. The OECD's evolving Pillar 2 global minimum tax framework adds a parallel pressure point: if U.S. domestic rates fall below the 15 percent Pillar 2 floor, foreign jurisdictions retain the right to collect top-up taxes on Pfizer's undertaxed foreign profits.

By the Numbers: Pfizer Lobbying Disclosure Spending

The first quarter 2026 filing (https://app.legis1.com/lda-filings/detail?id=2076734#summary) — one of several Pfizer has active this quarter — discloses $110,000 paid to Washington Tax and Public Policy Group LLC, a boutique firm specializing in tax and public policy. This filing covers only tax issues. It is a continuation of an existing relationship: Washington Tax and Public Policy Group filed a comparable Pfizer disclosure in the first quarter of 2025, reporting $30,000 for the same issue set.

Pfizer's total lobbying footprint is substantially larger. Across all registrants in the prior year, Pfizer's in-house lobbying alone ran into the millions per quarter — $3.71 million in Q2 2025, $2.81 million in Q3 2025, and $1.72 million in Q4 2025. The company simultaneously retains BGR Government Affairs LLC for general pharmaceutical and health policy counsel, Marshall & Popp LLC on drug pricing, Duberstein Group Inc. on PBM issues, Federal Health Policy Strategies LLC on IRA implementation, and Akin Gump Strauss Hauer & Feld LLP on trade and tariffs.

Washington Tax and Public Policy Group's sole listed lobbyist on this Pfizer pharmaceutical lobbying disclosure is Zach Price, a former staff assistant in the office of Sen. Dan Coats (R-IN). Price's work is narrowly focused on the TAX issue code — he is not a generalist but a subject-matter specialist brought in for complex international tax policy work.

Washington Tax and Public Policy Group carries a roster of clients with overlapping tax interests, including Regeneron Pharmaceuticals, ModernaTX, Johnson & Johnson, IBM, Hewlett Packard Enterprise, and the Alliance for Biopharmaceutical Competitiveness and Innovation — the firm's largest disclosed client at $950,000 over the period — all lobbying on the same IRC provisions as Pfizer.

--

The Agenda

No specific legislatio is listed but the disclosure states Pfizer is lobbying on "issues related to corporate and international taxation," OECD Pillar 1 and Pillar 2 negotiations, and IRC §§ 11, 951A, 250, 163(j), and 174.

Those sections govern some of the most consequential tax provisions for a multinational pharmaceutical company:

  • §951A (GILTI) taxes foreign earnings of U.S. multinationals. The One Big Beautiful Bill Act prevented a scheduled increase in the effective GILTI rate — a significant outcome for companies like Pfizer with substantial overseas income.
  • §250 provides the FDII and GILTI deductions that reduce U.S. tax on foreign-derived income. Legislation such as H.R. 1062 in the 119th Congress would make permanent the higher pre-2026 deduction rates.
  • §174 governs R&D expensing. Congress restored full domestic R&D expensing for tax years beginning January 1, 2025, though the 15-year amortization requirement for foreign R&D remains in place — a relevant carve-out for a company with global research operations.
  • §163(j) limits business interest deductions. The One Big Beautiful Bill Act modified this provision, with new rules taking effect for tax years beginning after December 31, 2025.
  • OECD Pillar 2 creates a 15 percent global minimum tax. A January 5, 2026 OECD package introduced a "side-by-side" safe harbor, and the G7 reached a joint understanding in June 2025 that prompted Congress to remove proposed Section 899 from the reconciliation bill — a significant development for U.S. multinationals' international tax planning.

There are relevant bills in the 119th Congress that could bear on these issues, including S. 1639, the American Innovation and Jobs Act, which addresses R&D expensing, and S. 1605, the International Competition for American Jobs Act, which addresses FDII and GILTI deduction rates.

Broader Context

The political environment surrounding this Pfizer government relations filing is charged. In March 2025, Sen. Ron Wyden (D-OR) released the findings of a four-year Senate Finance Committee investigation, accusing Pfizer of operating what he described as "what could be the largest tax-dodging scheme in the history of Big Pharma" — alleging the company reported zero taxable U.S. profits in 2019 despite $20 billion in U.S. drug sales.

Sens. Sheldon Whitehouse, Chris Van Hollen, and Elizabeth Warren amplified those findings in subsequent weeks.

On the other side of the aisle, House Ways and Means Chairman Jason Smith (R-MO) confirmed the reconciliation bill "stopped a scheduled tax increase to GILTI, BEAT, and FDII provisions" — a direct legislative win for companies in Pfizer's position. Sen. Mike Crapo (R-ID) cited U.S. Chamber of Commerce support for permanent R&D expensing and an expanded business interest limitation as key outcomes of the bill. The Ways and Means Committee was in active markup during the first quarter of 2026, with Chairman Smith and Crapo jointly announcing the removal of proposed Section 899 from the reconciliation bill following the G7 international tax agreement in June 2025.

Competitive Landscape

Pfizer is not alone in lobbying these provisions. RTX Corp. has filed on GILTI, FDII, §174, and Pillar 2 every quarter from 2022 through thirs quarter last year. General Mills lobbied on GILTI, FDII, §163(j), and §174 in both the second and third quarters of 2025. Amgen lobbied on corporate and international tax provisions including §174 R&D expensing. The National Foreign Trade Council has consistently lobbied on OECD Pillar 1 and 2, digital services taxes, §174, and §163(j) across multiple recent quarters. A dedicated Interest Deductibility Working Group has filed specifically on §163(j) reform, citing the same legislative vehicles as those relevant to Pfizer's disclosure.

The Bottom Line

The first quarter lobbying filing captures a company navigating significant legislative risk on multiple fronts simultaneously. It reflects a company using specialized outside tax counsel to engage on provisions that are simultaneously under Democratic attack and Republican protection. The legislative outcomes of the One Big Beautiful Bill Act — locking in GILTI and FDII rates, restoring R&D expensing, and modifying §163(j) — were directly relevant to Pfizer's disclosed lobbying interests. Whether those outcomes fully address Pfizer's concerns, or whether additional legislative or regulatory action on OECD Pillar 2 compliance creates new exposure, will determine whether this engagement continues or expands in subsequent quarters.

Access the Legis1 platform for comprehensive political news, data, and insights.